Pancreatic cancer is on the rise, ranking 13th among cancer sites in the world and 5th among digestive cancers. Real-life national data on patients with localized pancreatic adenocarcinoma are lacking in the medical literature given their number, which is often not representative because most diagnoses are made at the metastatic stage. The main objective of this study, which is part of the activity report of the Medical Oncology Department of the Hassan II University Hospital of Fez, is to report the survival results of localized pancreatic adenocarcinomas collected at the said department and to determine the prognostic factors associated with this survival depending on the year while comparing them to global results.
Cite this paper
Chouef, J. , Amaadour, L. , Medyouni, H. , Siyouri, O. , Elhakym, S. , Elhilali, H. , Oualla, K. , Benbrahim, Z. , Arifi, S. and Mellas, N. (2024). Descriptive Study of Localized Pancreas Cancers: Experience of CHU Hassan II of Fes. Open Access Library Journal, 11, e1384. doi: http://dx.doi.org/10.4236/oalib.1111384.
Global Cancer Statistics 2020 (2020) Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. https://pubmed.ncbi.nlm.nih.gov/33538338/
Ryan, D.P., Hong, T.S. and Bardeesy, N. (2014) Pancreatic Adenocarcinoma. The New England Journal of Medicine, 371, 1039-1049. https://doi.org/10.1056/NEJMra1404198
Schwarz, L. and Sa Cunha, A. (2014) The Resectability Criteria for Pancreatic Adenocarcinomas in 2014. Hépato-Gastro et Oncologie Digestive, 21, 727-736.
Katz, M.H., Marsh, R., Herman, J.M., et al. (2013) Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Annals of Surgical Oncology, 20, 2787-2795. https://doi.org/10.1245/s10434-013-2886-9
Neoptolemos, J.P., Stocken, D.D., Friess, H., et al. (2004) A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. The New England Journal of Medicine, 350, 1200-1210. https://doi.org/10.1056/NEJMoa032295
Oettle, H., Neuhaus, P., Hochhaus, A., et al. (2013) Adjuvant Chemotherapy with gEmcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA, 310, 1473-1481. https://doi.org/10.1001/jama.2013.279201
Regine, W.F., Winter, K.A., Abrams, R., et al. (2011) Fluorouracil-Based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial. Annals of Surgical Oncology, 18, 1319-1326. https://doi.org/10.1245/s10434-011-1630-6
Hartwig, W., Hackert, T., Hinz, U., et al. (2011) Pancreatic Cancer Surgery in the New Millennium. Better Prediction of Outcome. Annals of Surgery, 254, 311-319. https://doi.org/10.1097/SLA.0b013e31821fd334
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
Midha, S., Chawla, S. and Garg, P.K. (2016) Modifiable and Non-Modifiable Risk Factors for Pancreatic Cancer: A Review. Cancer Letters, 381, 269-277. https://doi.org/10.1016/j.canlet.2016.07.022
Wood, H.E., Gupta, S., Kang, J.Y., Quinn, M.J., Maxwell, J.D., Mudan, S. and Majeed, A. (2006) Pancreatic Cancer in England and Wales 1975-2000: Patterns and Trends in Incidence, Survival and Mortality. Alimentary Pharmacology & Therapeutics, 23, 1205-1214. https://doi.org/10.1111/j.1365-2036.2006.02860.x
Conroy, T., et al. (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. The New England Journal of Medicine, 379, 2395-2406. https://www.nejm.org/doi/full/10.1056/NEJMoa1809775
Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., et al. (2001) Adjuvant Chemoradiotherapy and Chemotherapy in Resectable Pancreatic Cancer: A Randomized Controlled Trial. The Lancet, 358, 1576-1585. https://doi.org/10.1016/S0140-6736(01)06651-X
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et al. (2007) Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA, 297, 267-277. https://doi.org/10.1001/jama.297.3.267
(1988) Treatment of Locally Unresectable Carcinoma of the Pancreas: Comparison of Combined-Modality Therapy (Chemotherapy Plus Radiotherapy) to Chemotherapy Alone. Gastrointestinal Tumor Study Group. Journal of the National Cancer Institute, 80, 751-755. https://pubmed.ncbi.nlm.nih.gov/2898536/
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C. and Ducreux, M. (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. The New England Journal of Medicine, 364, 1817-1825. https://doi.org/10.1056/NEJMoa1011923
Neuhaus, P., Riess, H., Post, S., et al. (2008) CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (Abstract). Journal of Clinical Oncology, 26. https://doi.org/10.1200/jco.2008.26.15_suppl.lba4504
Neoptolemos, J.P., Stocken, D.D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M.J., Gallinger, S., Mariette, C., Wente, M.N., Izbicki, J.R., Friess, H., Lerch, M.M., Dervenis, C., Oláh, A., Butturini, G., Doi, R., Lind, P.A., Smith, D., Valle, J.W., Palmer, D.H., Buckels, J.A., Thompson, J., McKay, C.J., Rawcliffe, C.L. and Büchler, M.W. (2010) European Study Group for Pancreatic Cancer Adjuvant Chemotherapy with Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial. JAMA, 304, Article 1073. https://doi.org/10.1001/jama.2010.1275
Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., Psarelli, E.E., Valle, J.W., Halloran, C.M., et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicenter, Open-Label, Randomized, Phase 3 Trial. The Lancet, 389, 1011-1024. https://doi.org/10.1016/S0140-6736(16)32409-6
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A.C., Raoul, J.L., et al. (2018) FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. The New England Journal of Medicine, 379, 2395-2406. https://doi.org/10.1056/NEJMoa1809775
Neoptolemos, J.P., Palmer, D.H., et al. (2017) Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet, 389, 1011-1024. https://pubmed.ncbi.nlm.nih.gov/28129987/
Valle, J.W., Palmer, D., et al. (2014) Optimal Duration and Timing of Adjuvant Chemotherapy after Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons from the ESPAC-3 Study. Journal of Clinical Oncology, 32, 504-512. https://pubmed.ncbi.nlm.nih.gov/24419109/
Versteijne, E., Vogel, J.A., Besselink, M.G., Busch, O.R.C., Wilmink, J.W., Daams, J.G., et al. (2018) Meta-Analysis Comparing Upfront Surgery with Neoadjuvant Treatment in Patients with Resectable or Borderline Resectable Pancreatic Cancer. British Journal of Surgery, 105, 946-958. https://doi.org/10.1002/bjs.10870
Hackert, T., Niesen, W., Hinz, U., Tjaden, C., Strobel, O., Ulrich, A., Michalski, C.W. and Büchler, M.W. (2017) Radical Surgery of Oligometastatic Pancreatic Cancer. European Journal of Surgical Oncology, 43, 358-363. https://pubmed.ncbi.nlm.nih.gov/27856064/
